384 related articles for article (PubMed ID: 16360021)
1. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.
Offner S; Hofmeister R; Romaniuk A; Kufer P; Baeuerle PA
Mol Immunol; 2006 Feb; 43(6):763-71. PubMed ID: 16360021
[TBL] [Abstract][Full Text] [Related]
2. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
[TBL] [Abstract][Full Text] [Related]
3. BiTEs: bispecific antibody constructs with unique anti-tumor activity.
Wolf E; Hofmeister R; Kufer P; Schlereth B; Baeuerle PA
Drug Discov Today; 2005 Sep; 10(18):1237-44. PubMed ID: 16213416
[TBL] [Abstract][Full Text] [Related]
4. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
5. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Brischwein K; Schlereth B; Guller B; Steiger C; Wolf A; Lutterbuese R; Offner S; Locher M; Urbig T; Raum T; Kleindienst P; Wimberger P; Kimmig R; Fichtner I; Kufer P; Hofmeister R; da Silva AJ; Baeuerle PA
Mol Immunol; 2006 Mar; 43(8):1129-43. PubMed ID: 16139892
[TBL] [Abstract][Full Text] [Related]
6. BiTE: Teaching antibodies to engage T-cells for cancer therapy.
Baeuerle PA; Kufer P; Bargou R
Curr Opin Mol Ther; 2009 Feb; 11(1):22-30. PubMed ID: 19169956
[TBL] [Abstract][Full Text] [Related]
7. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.
Hoffmann P; Hofmeister R; Brischwein K; Brandl C; Crommer S; Bargou R; Itin C; Prang N; Baeuerle PA
Int J Cancer; 2005 May; 115(1):98-104. PubMed ID: 15688411
[TBL] [Abstract][Full Text] [Related]
8. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
9. Bispecific T-cell engaging antibodies for cancer therapy.
Baeuerle PA; Reinhardt C
Cancer Res; 2009 Jun; 69(12):4941-4. PubMed ID: 19509221
[TBL] [Abstract][Full Text] [Related]
10. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibodies for polyclonal T-cell engagement.
Baeuerle PA; Kufer P; Lutterbüse R
Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
[TBL] [Abstract][Full Text] [Related]
12. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
Bortoletto N; Scotet E; Myamoto Y; D'Oro U; Lanzavecchia A
Eur J Immunol; 2002 Nov; 32(11):3102-7. PubMed ID: 12385030
[TBL] [Abstract][Full Text] [Related]
13. Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells.
Bühler P; Molnar E; Dopfer EP; Wolf P; Gierschner D; Wetterauer U; Schamel WW; Elsässer-Beile U
J Immunother; 2009; 32(6):565-73. PubMed ID: 19483653
[TBL] [Abstract][Full Text] [Related]
14. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses.
Stamova S; Feldmann A; Cartellieri M; Arndt C; Koristka S; Apel F; Wehner R; Schmitz M; Bornhäuser M; von Bonin M; Ehninger G; Bartsch H; Bachmann M
Anal Biochem; 2012 Apr; 423(2):261-8. PubMed ID: 22274538
[TBL] [Abstract][Full Text] [Related]
15. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
16. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
17. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing.
Grosse-Hovest L; Hartlapp I; Marwan W; Brem G; Rammensee HG; Jung G
Eur J Immunol; 2003 May; 33(5):1334-40. PubMed ID: 12731059
[TBL] [Abstract][Full Text] [Related]
18. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?
Chang CC; Campoli M; Ferrone S
Curr Opin Immunol; 2004 Oct; 16(5):644-50. PubMed ID: 15342012
[TBL] [Abstract][Full Text] [Related]
19. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
20. The effect of co-expression costimulatory molecule CD80 on uptake of antigen peptide-MHC class I-GFP complex by specific T cells.
Liu X; Zhang L; Zhang X; Yu H; Zhao X; Lu J; Qian G; Ge S
Int J Oncol; 2007 Jun; 30(6):1389-96. PubMed ID: 17487359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]